INDIANAPOLIS, Aug 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will host a conference call on Tuesday, August 26, 2008 at 5:00 p.m. EDT to discuss the recent FDA advisory on Byetta(R) (exenatide) injection. Participating in the call for Lilly will be Donald Therasse, M.D., vice president of global patient safety. Participating in the call for Amylin will be Daniel M. Bradbury, Amylin's president and chief executive officer, and Orville G. Kolterman, M.D., senior vice president of research and development.
Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at www.lilly.com or Amylin's website at www.amylin.com The webcast of the conference call will be available for replay through September 26, 2008. For those without access to the Internet, the live call may be accessed by phone by calling (866) 814-1915 (domestic) or (703) 639-1359 (international), passcode 1277182. A replay of the call will also be available by phone through September 26, 2008 beginning approximately one hour after the close of the call and can be accessed at (888) 266-2081 (domestic) or (703) 925-2533 (international), passcode 1277182.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. P-LLY
Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help health care professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products visit www.lillydiabetes.com.
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at www.amylin.com.
SOURCE Eli Lilly and Company
Copyright (C) 2008 PR Newswire. All rights reserved
News Provided by COMTEX